A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

NCT03088878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma

Interventions

DRUG: Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
DRUG: Cirmtuzumab (300mg) plus Ibrutinib
DRUG: Cirmtuzumab (600 mg) plus ibrutinib
DRUG: Cirmtuzumab (RDR) plus ibrutinib
DRUG: Cirmtuzumab plus ibrutinib
DRUG: Ibrutinib alone

Sponsor

Oncternal Therapeutics, Inc

Collaborators

[object Object]
[object Object]
[object Object]